Immatics N.V. (NASDAQ:IMTX) Stock Has Consensus Target Price of $19.00

Immatics N.V. (NASDAQ:IMTX) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $19.00.

A number of equities research analysts have recently issued reports on IMTX shares. Jefferies Financial Group set a $17.00 target price on shares of Immatics in a research report on Tuesday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research note on Friday, September 18th. Mizuho set a $21.00 price target on shares of Immatics in a research report on Thursday, October 29th. Stifel Nicolaus started coverage on shares of Immatics in a research report on Tuesday, October 13th. They set a “buy” rating and a $15.00 price target on the stock. Finally, Wall Street Zen cut shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st.

Immatics Trading Down 0.2%

NASDAQ:IMTX opened at $6.42 on Wednesday. The stock has a 50 day simple moving average of $7.89 and a 200 day simple moving average of $9.46. The stock has a market cap of $877.55 million, a P/E ratio of -3.45 and a beta of 1.38. Immatics has a 1-year low of $6.09 and a 1-year high of $12.41.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.07). The firm had revenue of $7.84 million during the quarter, compared to analyst estimates of $12.18 million. Immatics had a negative net margin of 495.71% and a negative return on equity of 47.41%. As a group, sell-side analysts forecast that Immatics will post -1.99 EPS for the current year.

Trending Headlines about Immatics

Here are the key news stories impacting Immatics this week:

• Neutral Sentiment: Immatics announced third-quarter 2026 financial results and a business update. The company describes itself as focused on precision targeting of PRAME, with clinical-stage cell therapy and bispecific programs; no specific new clinical results are included in the report summary. Immatics Announces Third Quarter 2026 Financial Results and Business Update
• Neutral Sentiment: A short-interest entry says short interest totaled zero shares as of November 10, despite describing a large increase. The figures are inconsistent and do not provide a reliable indication of short-selling pressure.
• Negative Sentiment: Immatics reported a third-quarter loss of $0.58 per share, wider than the $0.49 loss expected by Zacks and compared with a $0.49 loss a year earlier. Revenue was reported at $7.84 million, below the cited consensus estimate of $12.18 million. The earnings and revenue shortfalls could weigh on investor sentiment. Immatics Reports Q3 Loss, Lags Revenue Estimates

Insider Activity

In other Immatics news, Director Perceptive Advisors Llc bought 863,060 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were purchased at an average price of $8.69 per share, for a total transaction of $7,499,991.40. Following the transaction, the director directly owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This trade represents a 8.31% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Institutional Investors Weigh In On Immatics

Several institutional investors have recently made changes to their positions in the stock. Aberdeen Group plc grew its position in Immatics by 89.0% during the third quarter. Aberdeen Group plc now owns 1,235,460 shares of the company’s stock worth $10,847,000 after buying an additional 581,856 shares in the last quarter. Troluce Capital Advisors LLC bought a new position in Immatics during the 1st quarter worth $2,460,000. Wellington Management Group LLP increased its stake in Immatics by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 1,647,852 shares of the company’s stock worth $16,693,000 after acquiring an additional 85,960 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Immatics in the 1st quarter valued at $742,000. Finally, Alps Advisors Inc. raised its holdings in Immatics by 46.2% in the 3rd quarter. Alps Advisors Inc. now owns 198,239 shares of the company’s stock valued at $1,741,000 after acquiring an additional 62,640 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors.

About Immatics

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells. Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.